Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.. Daily Stock Analysis

Daily Stock Analysis, RETO, Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas., priceseries

Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.. Daily Stock Analysis
Stock Information
Open
1.25
Close
1.25
High
1.38
Low
1.25
Previous Close
1.31
Daily Price Gain
-0.06
YTD High
2.77
YTD High Date
Jan 21, 2022
YTD Low
0.62
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.22
YTD Gain
-14.97%
52 Week High
3.36
52 Week High Date
Nov 18, 2021
52 Week Low
0.62
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-0.37
52 Week Gain
-22.84%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Nov 12. 2018
2.90
Nov 15. 2018
3.10
3 Trading Days
6.98%
Link
LONG
Nov 29. 2018
2.56
Dec 3. 2018
2.71
2 Trading Days
6.05%
Link
LONG
Jan 17. 2019
1.82
Jan 28. 2019
1.97
6 Trading Days
8.43%
Link
LONG
Apr 17. 2019
1.75
Apr 29. 2019
1.86
7 Trading Days
6.20%
Link
LONG
Jul 1. 2019
1.16
Jul 9. 2019
1.31
5 Trading Days
13.23%
Link
LONG
Jan 29. 2020
1.15
Jan 31. 2020
1.29
2 Trading Days
12.23%
Link
LONG
Jun 19. 2020
1.10
Jul 6. 2020
1.25
10 Trading Days
13.62%
Link
LONG
Feb 3. 2021
0.94
Feb 18. 2021
1.19
10 Trading Days
26.21%
Link
LONG
Jun 4. 2021
1.11
Jun 17. 2021
1.23
9 Trading Days
10.75%
Link
LONG
Nov 8. 2021
1.13
Nov 19. 2021
1.89
9 Trading Days
67.15%
Link
LONG
Dec 20. 2021
0.87
Jan 5. 2022
1.44
11 Trading Days
64.78%
Link
LONG
Jan 13. 2022
1.48
Jan 21. 2022
1.71
5 Trading Days
15.88%
Link
LONG
Feb 3. 2022
1.16
Feb 10. 2022
1.23
5 Trading Days
5.82%
Link
Company Information
Stock Symbol
RETO
Exchange
NASDAQ
Company URL
http://www.reatapharma.com
Company Phone
972-865-2206
CEO
J. Warren Huff
Headquarters
Texas
Business Address
2801 GATEWAY DRIVE SUITE 150, IRVING, TX 75063
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001358762
About

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its products include cardiovascular, rare diseases, immune-oncology, and ophthalmology. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.

Description

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading